Published: Jul, 2019
The global anti-obesity prescription drugs market is expected to see promising growth in forthcoming year, as reported by Transparency Market Research (TMR). Because of the lower rate of achievement and removal of centralized drugs, several of the leading firms have regarded the manufacture of anti-obesity drugs as being prohibitively dangerous and have changed their drive to the extension of the diabetic range into obesity. As a powerful connection between type 2 diabetes and obesity has been established by various businesses, it is often regarded a low-risk strategy and a minor R&D investment in prospective medications for anti-obesity.
While the major players in the market have created a powerful footing for progressive market development, tiny and medium-sized players are far from building their market bases. The fresh and emerging market suppliers are anticipated, in order to improve growth opportunities, to follow the footsteps of established companies.
In the medical and healthcare sector, the global prescription anti-obesity drugs market is very much linked. The market suppliers are therefore expected to cooperate in order to increase chances of development with the medical organizations and health centers. In addition, worldwide market players in the prescription drug anti-obesity market should also be merged and purchased over the coming years.
Transparency Market Research (TMR) anticipates an increase of 4.80% in CAGR over the period from 2017 to 2026 in the worldwide market for anti-obesity medication. In addition, by the end of 2026, the world market's cumulative price of prescription anti-obesity medication will exceed US$ 1,000 million. Geographically speaking, anti-obesity prescription is the highest in North America, with the most used distribution channels emerging from hospital pharmacies.Changing Lifestyles to Propel Anti-Obesity Drugs Market
Due to its food consumption and eating patterns, the development of the market for anti-obesity prescription medicines has undergone ground-breaking changes over the previous decade. Increased obesity in the youth's liking for junk food has controlled the demand for prescription anti-obesity medication. The food products that are prepared in the restaurants use cholesterol-rich products and this technique of cooking has now been shifted into buildings. This is one of the prominent factors influencing the growth of the global anti-obesity prescription drugs market.
Market constraining factors are the higher costs in studies, development and production of prescriptive medicinal products, the increase in herbal weight loss products, the side effects of anti-obesity medicinal products, and the increased acceptance of alternative choices, such as the gyms, fitness spas. The development of the market for anti-prescription medicines is also anticipated to impede to some extent the increase in bio-free and fat-free products.
Emergence of Novel Innovations to Offer Rich Growth Opportunity
New technique for skin patch delivery of medicines that can allow anti-obesity medicines with a decreasing risk of side-effect, nano-based soy phytosome thermogels as a topical formula for anti-obesity, herbal supplements, obesity-related gene mutation is a fresh trend on the anti-obesity prescription drugs market.
OTC Drugs to Emerge as Key Market Trend
Orlistat is marketed under the business name Xenical by Roche in most nations as prescription medicinal products and is sold under the trade name Ally by GlaxoSmithKline as OTC medicinal products in the UK and the U.S. Currently, OTC drugs are much less approved on the market. Nevertheless, cost effectiveness and easy access to OTC goods should increase development on the market.
The rising prescription of psychotropic medicines, which are supposedly obesity, has also led to the worldwide market development for prescription medicines for anti-obesity. In addition to the use of antidepressants and diabetic medicines, the demand for prescription drugs on the worldwide market has risen. Obesity leadership has become an significant field in the health sector, creating growth spaces in the global anti-obesity prescription drugs market.
The study presented here is based on a report by Transparency Market Research (TMR) titled, “Anti-Obesity Prescription Drugs Market (By Drug Class - Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide; Age Group - Pediatric, Adult; Distribution Channel - Hospitals Pharmacies, Retail Pharmacies, E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2026.”
The report segments the global anti-obesity prescription drugs market along the following lines:
- Drug Class
- Bupropion and Naltrexone
- Phentermine and Topiramate
- Age Group
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- North America
- Latin America
- The Middle East and Africa
- Asia Pacific
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive data we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453